BMY vs. JAZZ: Bristol-Myers Squibb vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Jazz Pharmaceuticals (JAZZ) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Bristol-Myers Squibb (BMY) is heavily traded at around 10.85M shares per day, whereas Jazz Pharmaceuticals (JAZZ) sees a more moderate 878.80K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Bristol-Myers Squibb (BMY) at 44.01% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for BMY.

Bristol-Myers Squibb (BMY) at 18.47% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

Both Bristol-Myers Squibb (BMY) at 33.79% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Bristol-Myers Squibb (BMY) at -0.22% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Jazz Pharmaceuticals (JAZZ) reports EPS growth of -167.51%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Bristol-Myers Squibb (BMY) at 1.59 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but BMY is more stretched: Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile and Bristol-Myers Squibb (BMY) at 1.91 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bristol-Myers Squibb (BMY) at 13.78 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Bristol-Myers Squibb (BMY) at 5.43 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics